145 related articles for article (PubMed ID: 34560229)
21. Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma.
Liao H; Huang Y; Guo B; Liang B; Liu X; Ou H; Jiang C; Li X; Yang D
Am J Cancer Res; 2015; 5(1):125-39. PubMed ID: 25628925
[TBL] [Abstract][Full Text] [Related]
22. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
23. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial.
Morscher RJ; Brard C; Berlanga P; Marshall LV; André N; Rubino J; Aerts I; De Carli E; Corradini N; Nebchi S; Paoletti X; Mortimer P; Lacroix L; Pierron G; Schleiermacher G; Vassal G; Geoerger B
Eur J Cancer; 2021 Nov; 157():268-277. PubMed ID: 34543871
[TBL] [Abstract][Full Text] [Related]
24. A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study.
Lapointe S; Mason W; MacNeil M; Harlos C; Tsang R; Sederias J; Luchman HA; Weiss S; Rossiter JP; Tu D; Seymour L; Smoragiewicz M
Invest New Drugs; 2020 Aug; 38(4):1137-1144. PubMed ID: 31707687
[TBL] [Abstract][Full Text] [Related]
25. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
26. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
Montero JC; Chen X; Ocaña A; Pandiella A
Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
[TBL] [Abstract][Full Text] [Related]
27. Directly imaging the localisation and photosensitization properties of the pan-mTOR inhibitor, AZD2014, in living cancer cells.
Ahmed AR; Candeo A; D'Abrantes S; Needham SR; Yadav RB; Botchway SW; Parker AW
J Photochem Photobiol B; 2020 Dec; 213():112055. PubMed ID: 33142217
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Sagers JE; Beauchamp RL; Zhang Y; Vasilijic S; Wu L; DeSouza P; Seist R; Zhou W; Xu L; Ramesh V; Stankovic KM
Sci Rep; 2020 Mar; 10(1):4211. PubMed ID: 32144278
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting mTOR activity using AZD2014 increases autophagy in the mouse cerebral cortex.
Bensalem J; Fourrier C; Hein LK; Hassiotis S; Proud CG; Sargeant TJ
Neuropharmacology; 2021 Jun; 190():108541. PubMed ID: 33794244
[TBL] [Abstract][Full Text] [Related]
30. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
Matsubara S; Tsukasa K; Kuwahata T; Takao S
Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
[TBL] [Abstract][Full Text] [Related]
31. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
[TBL] [Abstract][Full Text] [Related]
32. Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity.
Syed F; Sanganee HJ; Singh S; Bahl A; Bayat A
J Invest Dermatol; 2013 May; 133(5):1340-50. PubMed ID: 23303455
[TBL] [Abstract][Full Text] [Related]
33. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
34. Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.
Ezell SA; Mayo M; Bihani T; Tepsuporn S; Wang S; Passino M; Grosskurth SE; Collins M; Parmentier J; Reimer C; Byth KF
Oncotarget; 2014 Jul; 5(13):4990-5001. PubMed ID: 24970801
[TBL] [Abstract][Full Text] [Related]
35. PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242.
Yang C; Huang X; Liu H; Xiao F; Wei J; You L; Qian W
Oncotarget; 2017 Jun; 8(24):39185-39197. PubMed ID: 28402933
[TBL] [Abstract][Full Text] [Related]
36. Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ; Berns K; Wisman GBA; Fehrmann RSN; Tomar T; Klip H; Meersma GJ; Hijmans EM; Gennissen AMC; Duiker EW; Weening D; Itamochi H; Kluin RJC; Reyners AKL; Birrer MJ; Salvesen HB; Vergote I; van Nieuwenhuysen E; Brenton J; Braicu EI; Kupryjanczyk J; Spiewankiewicz B; Mittempergher L; Bernards R; van der Zee AGJ; de Jong S
Clin Cancer Res; 2018 Aug; 24(16):3928-3940. PubMed ID: 29685880
[No Abstract] [Full Text] [Related]
37. CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
Kim J; Cho YJ; Ryu JY; Hwang I; Han HD; Ahn HJ; Kim WY; Cho H; Chung JY; Hewitt SM; Kim JH; Kim BG; Bae DS; Choi CH; Lee JW
Gynecol Oncol; 2020 Jan; 156(1):211-221. PubMed ID: 31776040
[TBL] [Abstract][Full Text] [Related]
38. CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization.
Mortensen DS; Fultz KE; Xu S; Xu W; Packard G; Khambatta G; Gamez JC; Leisten J; Zhao J; Apuy J; Ghoreishi K; Hickman M; Narla RK; Bissonette R; Richardson S; Peng SX; Perrin-Ninkovic S; Tran T; Shi T; Yang WQ; Tong Z; Cathers BE; Moghaddam MF; Canan SS; Worland P; Sankar S; Raymon HK
Mol Cancer Ther; 2015 Jun; 14(6):1295-305. PubMed ID: 25855786
[TBL] [Abstract][Full Text] [Related]
39. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling.
Zhang X; Qin T; Zhu Z; Hong F; Xu Y; Zhang X; Xu X; Ma A
Am J Med Sci; 2020 Feb; 359(2):123-129. PubMed ID: 32039764
[TBL] [Abstract][Full Text] [Related]
40. Combined mTORC1/mTORC2 inhibition blocks growth and induces catastrophic macropinocytosis in cancer cells.
Srivastava RK; Li C; Khan J; Banerjee NS; Chow LT; Athar M
Proc Natl Acad Sci U S A; 2019 Dec; 116(49):24583-24592. PubMed ID: 31732667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
